Key Points
- SiBone director Jeffrey Dunn sold 20,000 shares at an average price of $18.91, totaling $378,200 and reducing his position by 55.47% to 16,057 shares.
- SiBone’s latest quarterly results exceeded expectations, with adjusted EPS of negative $0.09 versus the consensus estimate of negative $0.15 and revenue of $56.01 million.
- Analysts maintain a generally positive outlook, with six Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $24.17; institutional investors own 98.11% of the stock.
SiBone (NASDAQ:SIBN - Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the business's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $18.91, for a total transaction of $378,200.00. Following the completion of the transaction, the director owned 16,057 shares in the company, valued at $303,637.87. The trade was a 55.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
SiBone Stock Performance
Shares of NASDAQ:SIBN opened at $18.64 on Friday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average price of $18.09 and a 200-day moving average price of $15.55. The company has a market cap of $826.68 million, a price-to-earnings ratio of -54.82 and a beta of 0.70. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The company had revenue of $56.01 million for the quarter, compared to analysts' expectations of $55.34 million. As a group, equities analysts anticipate that SiBone will post -0.4 EPS for the current year.
Hedge Funds Weigh In On SiBone
A number of institutional investors have recently bought and sold shares of the stock. UBS Group AG grew its holdings in shares of SiBone by 570.2% during the 4th quarter. UBS Group AG now owns 104,731 shares of the company's stock worth $2,065,000 after acquiring an additional 89,105 shares during the period. Dimensional Fund Advisors LP raised its position in shares of SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock worth $7,816,000 after acquiring an additional 182,465 shares in the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of SiBone in the 4th quarter worth approximately $838,000. HighMark Wealth Management LLC lifted its stake in shares of SiBone by 549.7% in the 4th quarter. HighMark Wealth Management LLC now owns 159,832 shares of the company's stock valued at $3,152,000 after purchasing an additional 135,232 shares during the period. Finally, Next Century Growth Investors LLC lifted its stake in shares of SiBone by 508.4% in the 4th quarter. Next Century Growth Investors LLC now owns 141,998 shares of the company's stock valued at $2,800,000 after purchasing an additional 118,657 shares during the period. 98.11% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on SIBN shares. UBS Group lifted their price objective on SiBone from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Truist Financial restated a "buy" rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. Weiss Ratings raised SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Finally, TD Cowen lifted their price target on shares of SiBone from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.17.
Check Out Our Latest Research Report on SIBN
About SiBone
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
